ARTICLE | Clinical News
Tirasemtiv: Phase IIb started
November 5, 2012 8:00 AM UTC
Cytokinetics began the international Phase IIb BENEFIT-ALS trial of oral tirasemtiv in about 400 ALS patients. Patients will receive twice-daily 125 mg tirasemtiv in a 1-week, open-label period follow...